Standard Nivolumab Dosing Schedules
Nivolumab (Opdivo), a PD-1 inhibitor for cancers like melanoma, lung cancer, and renal cell carcinoma, is typically dosed every 2, 3, or 4 weeks depending on the regimen and indication. Fixed doses are now standard (240 mg or 480 mg IV), replacing earlier weight-based dosing. A full course often spans 1-2 years or until disease progression/toxicity, equating to 26-104 doses in common schedules.[1]
How Many Doses in Melanoma Regimens?
In adjuvant melanoma treatment, nivolumab is given as 240 mg every 2 weeks for up to 1 year (52 doses maximum). For unresectable/metastatic melanoma combined with ipilimumab, it's 240 mg every 3 weeks for 4 doses, followed by 480 mg every 4 weeks until progression (initial phase: 4 doses; maintenance: ~13 doses/year).[1][2]
Dosing in Non-Small Cell Lung Cancer (NSCLC)
Monotherapy uses 240 mg every 2 weeks or 480 mg every 4 weeks until progression. Combined with ipilimumab, it's 360 mg every 3 weeks for 4 doses, then 480 mg every 4 weeks (initial: 4 doses; ongoing as needed). Typical duration: 1+ years, or 26+ doses.[1]
Regimens for Renal Cell Carcinoma and Other Cancers
With ipilimumab in first-line renal cell carcinoma, nivolumab is 240 mg every 3 weeks for 4 doses, followed by 480 mg every 4 weeks (4 initial + ~13/year). Similar for hepatocellular carcinoma or esophageal cancer. In Hodgkin lymphoma, 240 mg every 2 weeks until progression.[1]
Factors Affecting Total Doses
Treatment stops at complete response, progression, or unacceptable toxicity (e.g., immune-related adverse events in 20-30% of patients). Median duration across trials: 5-12 months (10-50 doses). No fixed upper limit; some patients receive 100+ doses long-term.[2][3]
Weight-Based vs. Fixed Dosing Shift
Pre-2021, dosing was 3 mg/kg every 2 weeks (e.g., 210 mg for 70 kg patient). Flat dosing simplifies administration without changing efficacy/safety.[1]
[1]: Opdivo Prescribing Information
[2]: FDA Label Updates
[3]: DrugPatentWatch.com - Nivolumab Patents and Exclusivity